Study guide
15.4 Diabetes, Glucose Homeostasis & Metabolic Syndrome
NBME Comprehensive Basic Science Examination CBSE
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Navigation
1.1 Current Exam Facts & Administration 1.2 Content Blueprint & Physician Tasks 1.3 Scoring, Score Reports & Step 1 Readiness
2 Human Development
2.1 Embryology & Congenital Development Patterns 2.2 Normal Age-Related Findings & Well-Patient Care
3 Blood & Hematologic Disease
3.1 Hematopoiesis, RBC Disorders & Anemias 3.2 Hemostasis, Thrombosis & Coagulopathies 3.3 WBC Disorders, Leukemia & Lymphoma Mechanisms
4 Immune System
4.1 Innate & Adaptive Immunity Mechanisms 4.2 Hypersensitivity, Autoimmunity & Immunodeficiency 4.3 Transplant Immunology & Immune Pharmacology
5 Nervous System Anatomy & Disease
5.1 Neuroanatomy Localization & Pathways 5.2 Stroke, Infection, Demyelination & Trauma 5.3 Seizures, Movement Disorders & Neurodegeneration 5.4 Special Senses: Eye & Ear Mechanisms
6 Behavioral Health
6.1 Psychiatric Disorders & Diagnostic Patterns 6.2 Psychopharmacology Mechanisms 6.3 Neurotransmitters, Learning & Behavioral Science
7 Musculoskeletal System
7.1 Bone Physiology, Fracture Healing & Bone Pathology 7.2 Joint Disease, Rheumatology & Connective Tissue 7.3 Muscle, NMJ & Peripheral Nerve Disorders
8 Skin & Soft Tissue
8.1 Dermatopathology High-Yield Lesions 8.2 Inflammation, Wound Healing & Soft-Tissue Infection
9 Cardiovascular Pathophysiology
9.1 Cardiac Cycle, Hemodynamics & Murmurs 9.2 Ischemic Heart Disease & Cardiomyopathy 9.3 Congenital & Valvular Heart Disease 9.4 Vascular Pathology & Hypertension
10 Cardiovascular Pharmacology
10.1 Antihypertensives, Heart Failure & Antiarrhythmics 10.2 Antiplatelets, Anticoagulants & Lipid Drugs
11 Respiratory System
11.1 Pulmonary Mechanics & Gas Exchange 11.2 Obstructive, Restrictive & Vascular Lung Disease 11.3 Pulmonary Infections, Neoplasms & Respiratory Pharmacology
12 Renal Physiology & Electrolytes
12.1 Nephron Transport & Renal Physiology 12.2 Electrolyte Disorders 12.3 Acid-Base Physiology & Compensation
13 Renal Pathology
13.1 Glomerular Disease Mechanisms 13.2 Tubulointerstitial, Vascular & Stone Disease
14 Gastrointestinal System
14.1 GI Physiology, Motility & Digestion 14.2 Esophagus, Stomach & Intestinal Pathology 14.3 Liver, Biliary Tree & Pancreas 14.4 GI Microbiology, Nutrition & Malabsorption
15 Endocrine System
15.1 Hormone Signaling & Hypothalamic-Pituitary Axes 15.2 Thyroid & Parathyroid Disease 15.3 Adrenal Disorders & Steroid Pharmacology 15.4 Diabetes, Glucose Homeostasis & Metabolic Syndrome
16 Reproductive System
16.1 Male & Female Reproductive Physiology 16.2 Pregnancy, Placenta & Developmental Toxicology 16.3 Reproductive Pathology & Hormone-Related Neoplasia
17 Multisystem Processes & Disorders
17.1 Cell Injury, Inflammation & Repair 17.2 Neoplasia Principles & Tumor Biology 17.3 Infection, Sepsis & Multisystem Microbial Disease 17.4 Genetics, Inborn Errors & Environmental Toxicology
18 Biostatistics & Epidemiology
18.1 Study Design, Bias & Causation 18.2 Diagnostic Test Metrics & Screening 18.3 Epidemiology Measures & Population Health
19 Social Sciences & Communication
19.1 Ethics Principles & Decision-Making Capacity 19.2 Communication Skills & Difficult Conversations 19.3 Professionalism, Systems & Practice-Based Learning
20 Integrated Disciplines Capstone
20.1 High-Yield Microbiology Anchors Across Systems 20.2 High-Yield Biochemistry & Molecular Mechanisms 20.3 Integrated Pharmacology Strategy & Exam-Day Execution
15.4 Diabetes, Glucose Homeostasis & Metabolic Syndrome
Key Takeaways Explain This Topic AI
Insulin is cleaved from proinsulin (C-peptide marker of endogenous secretion); glucose enters β cells via GLUT2 → ATP closes KATP → depolarization → Ca2+ influx → insulin release; GLUT4 is insulin-responsive in muscle/adipose.
T1DM is autoimmune β-cell destruction (HLA-DR3/DR4, autoantibodies) with absolute insulin deficiency; T2DM is insulin resistance plus relative β-cell failure with amylin/amyloid and progressive secretory defect.
DKA (usually T1): insulinopenia → lipolysis → ketogenesis, anion-gap acidosis, dehydration; HHS (usually T2): profound hyperglycemia/hyperosmolarity without significant ketoacidosis.
Chronic complications: microangiopathy (AGEs, sorbitol, PKC pathways) → retinopathy, nephropathy, neuropathy; macrovascular atherosclerosis drives MI/stroke/PAD risk.
High-yield drug mechanisms: metformin (↓hepatic gluconeogenesis, AMPK); sulfonylureas (close β-cell KATP); GLP-1 agonists/DPP-4 inhibitors (incretin axis); SGLT2 inhibitors (urinary glucose loss); TZDs (PPAR-γ insulin sensitizers).
Last updated: August 2026
15.4 Diabetes, Glucose Homeostasis & Metabolic Syndrome
Quick Answer: Glucose → GLUT2 β cell → ↑ATP → close KATP → insulin (± C-peptide). GLUT4 stores fuel in muscle/fat. T1 = autoimmune absolute deficiency; T2 = resistance + relative deficiency. DKA = ketosis/acidosis; HHS = extreme hyperosmolarity. Know metformin, SU, GLP-1, DPP-4, SGLT2, TZD mechanisms and micro- vs macrovascular complication logic.
Metabolic endocrine content is heavily tested because it links cell biology, pathology, and pharmacology in one system. Master the β-cell stimulus–secretion coupling first; everything else is a perturbation of that loop or of insulin action in target tissues.
Insulin Synthesis, Secretion, and GLUT Transporters
β cells synthesize preproinsulin → proinsulin → insulin + C-peptide in equimolar amounts. C-peptide measures endogenous insulin secretion (absent in exogenous insulin injection; low in T1DM; variable in T2DM).
Stimulus–secretion coupling:
Glucose enters β cells via GLUT2 (insulin-independent).
Glucokinase phosphorylates glucose (glucose sensor; MODY2 when mutated).
Metabolism raises ATP/ADP .
ATP closes the ATP-sensitive K+ channel (KATP, SUR1/Kir6.2) .
Membrane depolarizes → voltage-gated Ca2+ channels open → Ca2+ influx → insulin granule exocytosis.
Sulfonylureas and meglitinides close KATP pharmacologically; diazoxide opens it (inhibits insulin release). Incretins (GLP-1, GIP) amplify glucose-stimulated insulin secretion via cAMP.
- Transporter Location Insulin-dependent? Role
- GLUT1 RBCs, brain (basal), placenta No Basal uptake
- GLUT2 β cell, liver, kidney, intestine No Glucose sensing/bidirectional hepatic flux
- GLUT3 Neurons No High-affinity brain uptake
- GLUT4 Skeletal muscle, adipose Yes Postprandial disposal
- SGLT1/2 Intestine/kidney (secondary active) No Na+-coupled absorption/reabsorption
Insulin receptor is a receptor tyrosine kinase . Downstream IRS → PI3K–Akt pathway mediates GLUT4 translocation and metabolic effects; MAPK pathway contributes to growth effects.
Counterregulatory Hormones
When glucose falls, counterregulation defends the brain:
- Glucagon (α cells): glycogenolysis, gluconeogenesis, ketogenesis permission
- Epinephrine : rapid glycogenolysis, lipolysis, symptoms of hypoglycemia
- Cortisol and GH : longer-term insulin resistance and gluconeogenic support
Hypoglycemia unawareness after recurrent lows reflects blunted counterregulatory responses—clinically critical though mechanism depth varies by exam item.
Fed state: high insulin/glucagon ratio → glycogen synthesis, lipogenesis, protein synthesis. Fasted state: low insulin/glucagon → glycogenolysis, gluconeogenesis, lipolysis, ketogenesis.
- Type 1 vs Type 2 Diabetes Mellitus
- Type 1 DM
Autoimmune destruction of β cells (type IVa hypersensitivity patterns with T-cell mediation). Associated with HLA-DR3 and DR4 , autoantibodies (anti-GAD65, IA-2, insulin autoantibodies) useful early. Absolute insulin deficiency → hyperglycemia and unrestrained lipolysis/ketogenesis when insulin is absent. Peak childhood/adolescence but adult latent autoimmune diabetes exists. Patients are often lean at onset; DKA is the classic acute presentation.
Type 2 DM
Insulin resistance in muscle, liver, and adipose (obesity, free fatty acids, inflammatory adipokines) plus progressive β-cell dysfunction (relative insulin deficiency). Islet amyloid (amylin) deposits are histologic associations. Stronger lifestyle and polygenic risk; acanthosis nigricans signals resistance. HHS is the classic hyperglycemic crisis more than DKA, though ketosis-prone T2 exists.
- Feature T1DM T2DM
- Primary lesion Autoimmune β-cell loss Resistance + β-cell failure
- Insulin/C-peptide Very low Normal/high early, later low
- Body habitus Often lean Often overweight/obese
- Ketosis tendency High Lower (not zero)
- Twin concordance Moderate High
- Treatment core Insulin essential Lifestyle ± non-insulin agents ± insulin
- DKA vs HHS Pathophysiology
Diabetic ketoacidosis (DKA): usually T1. Absolute insulin deficiency + counterregulatory excess → hyperglycemia (osmotic diuresis, dehydration, electrolyte depletion) and hormone-sensitive lipase activation → free fatty acids → hepatic ketogenesis (β-hydroxybutyrate, acetoacetate) → anion-gap metabolic acidosis . Kussmaul breathing, fruity breath, abdominal pain, altered mentation. Total-body K+ depleted despite possible hyperkalemia from acidosis/insulin lack—exam favorite. Triggers: infection, insulin omission, new-onset disease.
Hyperosmolar hyperglycemic state (HHS): usually older T2 patients. Enough insulin to suppress ketogenesis but not to prevent severe hyperglycemia → extreme hyperosmolarity , profound dehydration, neurologic changes; minimal ketones/acidosis . Mortality historically higher than DKA; fluid resuscitation is central conceptually.
- DKA HHS
- Typical patient T1, younger T2, older
- Glucose High (often 300–600 mg/dL range conceptually) Often higher (e.g., >600)
- Ketones/acidosis Prominent anion-gap acidosis Absent/minimal
- Osmolality Elevated Markedly elevated
- Key driver Insulinopenia → ketogenesis Relative insulin + severe dehydration
- Hypoglycemia
Neuroglycopenic symptoms (confusion, seizure, coma) and autonomic symptoms (sweating, tremor, palpitations). Causes: excess insulin/secretagogue, missed meals, exercise, critical illness, insulinoma (high insulin + high C-peptide + low glucose), exogenous insulin (high insulin, low C-peptide). Factitious sulfonylurea use mimics insulinoma biochemically until drug screen—classic distinction.
Chronic Complications: Micro and Macrovascular
Chronic hyperglycemia drives:
Advanced glycation end products (AGEs) cross-linking matrix proteins and activating RAGE inflammatory signaling
- Polyol (sorbitol) pathway via aldose reductase → osmotic/oxidative stress (lens, nerves, Schwann cells)
- Protein kinase C activation from de novo DAG synthesis → vascular dysfunction
- Hexosamine pathway excess
Microvascular (more glucose-specific, improved by glycemic control trials historically):
Retinopathy: pericyte loss, microaneurysms, hemorrhages, neovascularization (VEGF) in proliferative disease
Nephropathy: mesangial expansion, GBM thickening, nodular glomerulosclerosis (Kimmelstiel–Wilson), albuminuria; ACEI/ARB renoprotective concepts
Neuropathy: distal symmetric polyneuropathy, autonomic neuropathy (gastroparesis, orthostasis, silent ischemia)
Macrovascular: accelerated atherosclerosis → coronary disease, stroke, peripheral arterial disease. Endothelial dysfunction, dyslipidemia pattern (high TG, low HDL, small dense LDL in insulin resistance). Glycemic control alone is less dominant than for microvascular disease—blood pressure and lipids matter enormously.
Metabolic Syndrome
Cluster of insulin resistance features (definitions vary slightly by organization): central obesity, hypertension, hyperglycemia/impaired fasting glucose, hypertriglyceridemia, low HDL. Shared pathophysiology: visceral adipose inflammation, free fatty acids, hepatic steatosis risk. Marks elevated ASCVD and T2DM risk—treat the components.
High-Yield Antihyperglycemic Mechanisms (CBSE Level)
Class Prototype idea Primary mechanism Notable effects / pearls
Biguanide Metformin ↓ hepatic gluconeogenesis (AMPK-related); ↑ insulin sensitivity modestly First-line T2; GI side effects; lactic acidosis risk in severe renal/hypoxic states
Sulfonylureas Glipizide, glyburide Close β-cell KATP → insulin release Hypoglycemia, weight gain; need functioning β cells
Meglitinides Repaglinide Shorter-acting KATP closure Mealtime secretagogue
GLP-1 receptor agonists Exenatide, liraglutide, etc. Incretin: ↑ glucose-dependent insulin, ↓ glucagon, slow gastric emptying, satiety Weight loss; low intrinsic hypo risk alone; nausea; injection
DPP-4 inhibitors Sitagliptin Block degradation of endogenous GLP-1/GIP Weight neutral; milder than GLP-1 RAs
SGLT2 inhibitors Canagliflozin, empagliflozin, etc. Block renal proximal glucose reabsorption → glucosuria Weight loss, BP ↓; genital mycotic infections; osmotic diuresis; cardio-renal outcome fame
TZDs Pioglitazone PPAR-γ agonists → insulin sensitization in adipose Weight gain, edema, heart failure caution, bone fracture risk
- α-glucosidase inhibitors Acarbose Block brush-border carb breakdown Flatulence; ↓ postprandial glucose
- Insulin Multiple analogs Activate insulin RTK Essential in T1; hypo and weight gain risks
Amylin analog (pramlintide) slows gastric emptying and suppresses glucagon—adjunct concept. Acarbose is less US-central but mechanism-clean for exams.
Clinical Vignette Reflexes
Newly diagnosed thin teen with polyuria, polydipsia, weight loss, and Kussmaul respirations = T1 DKA until proven otherwise. Older obese patient with glucose 900 mg/dL, stupor, minimal acidosis = HHS. Acanthosis nigricans + central obesity = insulin resistance/metabolic syndrome. Postprandial hypoglycemia after SU overdose = KATP closure toxicity. Rising creatinine and albuminuria after years of diabetes = microvascular nephropathy pathways. Choosing metformin first in uncomplicated T2 reflects hepatic gluconeogenesis suppression without hypoglycemia as monotherapy.
If you can draw β-cell depolarization, name the four major GLUT roles, split DKA from HHS in one sentence each, and recite the six core drug mechanisms in the table, you have covered the vast majority of CBSE diabetes and intermediate metabolism items in the reproductive–endocrine content band.